New cancer drugs: Roche's divarasib cuts risk of death in a lung cancer trial and AstraZeneca's stomach cancer drug extends survival
Roche says its drug divarasib cut the risk of death by 44% and of disease progression or death by 42% compared with first-generation drugs in a phase III trial in previously treated KRAS G12C lung cancer.
Left 0 · Centre-left 1 · Centre 2 · Centre-right 1 · Right 0
ContextSources by leanVideoDeep diveFollow the moneyMore coverage
How each side framed it
Left-leaning outlets
Left-rated outlets headline it: “Roche Drug Outshines Amgen, Bristol Rivals in Lung Cancer Study” (Bloomberg).
Centre outlets
Centre-rated outlets headline it: “Roche says divarasib cut risk of death 44% in lung cancer trial” (Reuters); “Roche’s divarasib demonstrated best-in-class efficacy, advancing the standard of care in previously treated KRAS G12C-mutated lung cancer – Company Announcement - FT.com” (Financial Times).
Right-leaning outlets
Right-rated outlets headline it: “Roche Targets Emerging Oncology Market With New Lung-Cancer Drug” (Wall Street Journal).
Context
We write the background for the day's biggest stories; for this one, start with these searches. How it works.
Search for more (live results, not checked by us): Wikipedia search · Explainers (Google News search) · Background and history (Google News search)
Sources by lean
Balanced: the same number of articles from the left, the centre and the right (up to 3 each). The bar above still counts every rated outlet we found. Bias and factual ratings come from Media Bias/Fact Check. How we balance · All ratings.
Left 1
- Bloomberg
Roche Drug Outshines Amgen, Bristol Rivals in Lung Cancer Study (paywalled or blocks bots)
Centre 1
Right 1
- Wall Street Journal
Roche Targets Emerging Oncology Market With New Lung-Cancer Drug
Showing 1 from each side of 4 rated outlets (L 1 / C 2 / R 1). Capped at 1 because that is all we found on the thinnest side. More coverage
Video
News reports, explainers and podcasts on YouTube. We pick and balance videos for the day's biggest stories; for this one, use these searches. Links open YouTube, which has its own privacy policy; nothing from YouTube loads on this page.
YouTube searches (live results, not checked or balanced by us): News videos · Explainers · Podcasts
Deep dive
A short prompt for thinking it through. We write a fuller side-by-side deep dive for the day's biggest stories.
A question to hold: What would each side need to see to change its mind?
Try it: open one left and one right article in Sources by lean and note what each takes for granted.
Follow the money
Not yet researched. We haven't yet looked at who gains or loses financially from this story, or who funds the main voices on each side. When we do, we check company filings, the Electoral Commission donations register, lobbying registers, annual reports, InfluenceMap and OpenSecrets, and we apply the same checks to every side. How we follow the money.
Who owns or funds the outlets covering this story (4 outlets)
| Outlet | Lean | Ownership & funding (MBFC) |
|---|---|---|
| Bloomberg | Centre-left | Michael R. Bloomberg is the founder and majority owner of Bloomberg LP (The parent company of Bloomberg News). According to Investopedia, Bloomberg Terminal (remote software used to access financial information) is the most expensive among financial data providers. source |
| Financial Times | Centre | The Financial Times is owned by The Nikkei, a Japanese news and financial information company that publishes the leading financial paper, The Nikkei. The FT generates revenue through subscriptions, a hard paywall, and advertising..push({}); source |
| Reuters | Centre | In April 2008, the British company Reuters Group was acquired by Thomson Corporation and formed Thomson Reuters. source |
| Wall Street Journal | Centre-right | In 2007, The Bancroft family and relatives sold the Wall Street Journal to Rupert Murdoch for 5 billion dollars. Rupert Murdoch also purchased its parent company, Dow Jones & Co., through News Corporation. Subscriptions and advertising fund the Wall Street Journal. source |